Background Evidence on the advantages of merging cyclooxygenase-2 inhibitor (COX-2) in
Background Evidence on the advantages of merging cyclooxygenase-2 inhibitor (COX-2) in treating non-small cell lung cancers (NSCLC) continues to be controversial. 95% CI: 1.20, 1.63), and first-line treatment (RR = 1.39, 95% CI: 1.19, 1.63). Nevertheless, COX-2 inhibitors AST 487 IC50 acquired no influence on the one-year success, Operating-system, and PFS. Elevated RR of leucopenia … [Read more…]